Ironwood Pharmaceuticals (IRWD) to Release Quarterly Earnings on Thursday

Ironwood Pharmaceuticals (NASDAQ:IRWD) is expected to be announcing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of $0.32 per share and revenue of $114.8430 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.01). Ironwood Pharmaceuticals had a negative return on equity of 39.65% and a net margin of 28.26%.The business had revenue of $106.51 million for the quarter, compared to analyst estimates of $92.11 million. On average, analysts expect Ironwood Pharmaceuticals to post $1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Ironwood Pharmaceuticals Trading Up 4.5%

Shares of NASDAQ:IRWD opened at $4.42 on Tuesday. The firm has a market cap of $720.73 million, a price-to-earnings ratio of 7.37 and a beta of 0.20. The stock’s 50-day moving average price is $3.86 and its two-hundred day moving average price is $3.97. Ironwood Pharmaceuticals has a 12-month low of $0.71 and a 12-month high of $5.78.

Analyst Ratings Changes

IRWD has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a research report on Friday, July 24th. Wall Street Zen raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Sunday, May 17th. Finally, Zacks Research cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Ironwood Pharmaceuticals currently has an average rating of “Hold” and an average target price of $6.23.

Insider Transactions at Ironwood Pharmaceuticals

In other news, insider Ronald Silver sold 127,890 shares of the company’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $4.52, for a total value of $578,062.80. Following the completion of the sale, the insider owned 313,680 shares of the company’s stock, valued at $1,417,833.60. This represents a 28.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Julie Mchugh sold 21,571 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $3.73, for a total value of $80,459.83. Following the completion of the transaction, the director owned 250,749 shares of the company’s stock, valued at approximately $935,293.77. This represents a 7.92% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 9.30% of the company’s stock.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Integrated Wealth Concepts LLC grew its stake in Ironwood Pharmaceuticals by 21.4% in the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 3,406 shares in the last quarter. Captrust Financial Advisors bought a new stake in shares of Ironwood Pharmaceuticals during the 2nd quarter valued at about $32,000. Jump Financial LLC acquired a new stake in Ironwood Pharmaceuticals during the fourth quarter worth about $34,000. Cibc World Markets Corp bought a new position in Ironwood Pharmaceuticals in the fourth quarter worth about $36,000. Finally, Vise Technologies Inc. acquired a new position in Ironwood Pharmaceuticals in the third quarter valued at approximately $39,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.